Objective:

To evaluate the potential success of oral GLP-1 receptor agonists based on manufacturing capabilities rather than just patient convenience.

Key Findings:

• Oral GLP-1s must overcome significant manufacturing challenges to compete with peptide GLP-1s.
• The production of peptide GLP-1s is capital-intensive and less scalable compared to small molecules.
• Patient preference for oral dosing is important, but manufacturing economics will ultimately dictate market success.

Interpretation:

The future of GLP-1 therapies will depend on the ability of small molecules to deliver comparable efficacy and safety while being manufacturable at scale, addressing both patient needs and production limitations.

Limitations:

• Some small molecule candidates have stalled due to efficacy or safety concerns.
• Oral GLP-1s may require higher dosages, complicating manufacturing and cost-effectiveness.

Conclusion:

Both peptide and small molecule GLP-1s will likely coexist in the market, with success hinging on efficient manufacturing processes and the ability to meet patient needs.